Lisinopril and simvastatin
Pro Research Analysisby 
Searched over 200M research papers
Effects of Lisinopril and Simvastatin on Hypertensive Patients
Introduction to Lisinopril and Simvastatin
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, and simvastatin, a statin, are commonly prescribed medications for managing hypertension and hypercholesterolemia, respectively. These drugs not only help in controlling blood pressure and cholesterol levels but also exhibit significant effects on various biochemical pathways and cellular functions.
Impact on Erythrocyte Antioxidant Enzymes
Lisinopril and Simvastatin on Antioxidant Enzyme Activities
Studies have shown that both lisinopril and the combination of lisinopril with simvastatin significantly affect the activities of antioxidant enzymes in erythrocytes. Specifically, these treatments increase catalase activity and decrease glutathione peroxidase activity in a majority of patients after 12 and 24 weeks of treatment . Superoxide dismutase activity also increases significantly after 24 weeks of treatment with either therapy . These changes suggest that both treatments can enhance the antioxidative defense mechanisms in erythrocytes, potentially protecting cells from oxidative damage.
Effects on Arginase and Nitric Oxide Metabolites
Modulation of Arginase and Nitric Oxide Synthase
Lisinopril and the combination therapy with simvastatin have been found to normalize the elevated arginase activity in erythrocytes of hypertensive patients. Both treatments also increase the concentrations of nitric oxide metabolites (NO2−, NO3−) in plasma, which are crucial for vascular health . This normalization of arginase activity and increase in nitric oxide metabolites suggest that these therapies can improve endothelial function and reduce vascular resistance, contributing to better blood pressure control.
Combined Therapy in Nephropathy
Benefits in Severe Experimental Nephropathy
In a severe rat model of nephropathy, the combination of lisinopril and simvastatin showed a remarkable antiproteinuric effect, significantly reducing proteinuria compared to either treatment alone. This combination therapy also improved renal function and limited glomerulosclerosis, tubular damage, and interstitial inflammation. These findings indicate that the combined use of an ACE inhibitor and a statin could be a potent therapeutic strategy for patients with advanced renal disease.
Cardiovascular Risk Reduction
Efficacy in a Polypill Formulation
A study on a polypill containing lisinopril, simvastatin, aspirin, and hydrochlorothiazide demonstrated significant reductions in systolic blood pressure and LDL-cholesterol levels over 12 weeks. However, the polypill also caused side effects in about 1 in 6 people, which were mostly mild and did not necessitate discontinuation of the treatment. This suggests that while the polypill can effectively reduce cardiovascular risk, patient tolerance and side effects need to be carefully managed.
Conclusion
Lisinopril and simvastatin, both individually and in combination, exhibit significant benefits in managing hypertension and hypercholesterolemia. They improve antioxidant enzyme activities, normalize arginase and nitric oxide synthase activities, and offer protective effects in severe nephropathy. However, the potential for side effects, especially in combination therapies, necessitates careful patient monitoring. Overall, these medications provide a robust approach to managing cardiovascular and renal complications in hypertensive patients.
Sources and full results
Most relevant research papers on this topic